Adjuvant Chemotherapy for Stage II Colon Cancer

Adjuvant chemotherapy for stage II colon cancer is intended to eliminate microscopic residual disease following curative surgical resection and thus reduce the risk of recurrence. While surgery alone achieves high cure rates of around 80 percent in unselected stage II patients, certain high-risk features—including T4 tumours, poor differentiation, lymphovascular or perineural invasion, insufficient nodal sampling and molecular markers such as deficient mismatch repair—identify subgroups with elevated relapse rates. Oxaliplatin-based regimens (FOLFOX) and fluoropyrimidine monotherapy (for example, capecitabine or 5-fluorouracil/leucovorin) are commonly used, but the absolute benefit in average-risk stage II disease remains modest. Decision algorithms now incorporate tumour histopathology, clinical parameters and emerging biomarkers to stratify patients. Ongoing efforts focus on integrating quantitative imaging and molecular signatures to refine risk assessment and guide personalised adjuvant therapy. The global significance lies in optimising benefit while sparing patients unnecessary toxicity and cost.

Research from Nature Portfolio

Multifractal analysis of histomorphological complexity has emerged as a promising tool to predict benefit from adjuvant treatment. Computer-aided evaluation of tumour–stroma interfaces yielded an “αmax” metric that outperformed conventional histological features in identifying patients most likely to derive recurrence-free survival advantage. This approach represents one of the first morphology-based biomarkers demonstrating significant interaction with chemotherapy in a randomised trial setting. Separately, an investigation of patients aged over 70 years found no significant improvement in recurrence-free, cancer-specific or overall survival with postoperative adjuvant chemotherapy. This real-world cohort study highlights the need for age-adapted risk stratification and suggests that chronological age alone should not dictate therapy, but rather a composite of frailty, comorbidity and tumour biology.

Adjuvant Chemotherapy for Stage II Colon Cancer publication trend

The graph below shows the total number of articles in adjuvant chemotherapy for stage ii colon cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Adjuvant chemotherapy: Drug treatment given after surgical removal of a tumour to eradicate microscopic disease and lower recurrence risk.

Stage II colon cancer: Disease in which the tumour has penetrated the bowel wall but has not spread to regional lymph nodes or distant sites.

Disease-free survival (DFS): The interval after treatment during which a patient shows no signs of cancer recurrence.

Radiomics: High-throughput extraction of quantitative features from medical images to characterise tumour phenotype.

Multifractal analysis: A mathematical method that quantifies complex patterns and heterogeneity within tissue architecture as potential biomarkers.

References

1. Adjuvant Chemotherapy for Stage II Colon Cancer. Cancers (2020).
2. Image analysis-derived metrics of histomorphological complexity predicts prognosis and treatment response in stage II-III colon cancer. Scientific Reports (2016).
3. Adjuvant chemotherapy does not provide survival benefits to elderly patients with stage II colon cancer. Scientific Reports (2019).
4. Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201). BMC Cancer (2022).
5. CT-Based Radiomics Signature: A Potential Biomarker for Predicting Postoperative Recurrence Risk in Stage II Colorectal Cancer. Frontiers in Oncology (2021).
6. Association of chemotherapy with survival in stage II colon cancer patients who received radical surgery: a retrospective cohort study. BMC Cancer (2021).